ArticleJournal of clinical medicine2025

Punctate Hyperfluorescence as a Favorable Predictive Factor for Treatment Response Following a Switch to Brolucizumab for Patients with Aflibercept-Refractory Neovascular Age-Related Macular Degeneration.

Hiroyuki Kamao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.